[anecdote]Triple agonist (GLP-1 + GIP + glucagon), 39 amino acids — Lily is reportedly trying to push it >40 aa to classify it as a biologic (much longer patent; blocks compounding). Newer GLP-class agents report less GI nausea. — Bakri 02:33–02:35
[educational] Part of the GLP-1-receptor class (retatrutide = GLP-1 + GIP + glucagon); averages ~25% body-weight loss, higher than oral semaglutide’s ~15%. Start low, titrate slow. — Oral GLP-1 review ~00:52
[educational] GLP-1 class ranked the #1 longevity peptide group; shares the class’s beyond-weight longevity mechanisms (anti-inflammatory, neuroprotective, mitochondrial, anti-senescence). — Longevity Top-5
[literature] GLP-1-class cancer-protective signal (ASCO 2026 metastatic-progression data across lung/breast/colorectal/liver). Observational; reinforces the longevity case. — SOURCE-asco2026-glp1-cancer-progression
[literature]Phase 3 confirmation — TRIUMPH-1 (May 2026): up to 28.3% weight loss at 12 mg over 80 wk (45.3% lost ≥30%); TRIUMPH-4 added 75.8% OA-pain reduction + ~20% LDL drop. First Phase 3 data (prior KB evidence was Phase 2 ~24%). Topline tier; full publication pending. — SOURCE-retatrutide-triumph1-phase3
Physician protocols
[protocol] GLP-1 class — micro-dose and titrate slowly; ≤2 lb/week to preserve lean mass; pair with protein + resistance training. — Koniver 00:15–00:16